Olema Pharmaceuticals, Inc. Share Price Today, Financials & AI Analysis — Stockinder

Jarvis is thinking

Olema Pharmaceuticals, Inc. Share Price Today, Financials & AI Analysis — Stockinder

Income Statement

	2025-12-31	2024-12-31	2022-12-31	2021-12-31
Profit from core operations after subtracting the cost of revenue and operating expenses like R&D and marketing, but before interest and taxes.	-$178.70M	-$142.26M	-$106.99M	-$71.49M
The company's bottom-line profit after all expenses, interest, and taxes are subtracted.	-$162.45M	-$129.47M	-$104.79M	-$71.10M
Net income divided by the number of shares outstanding — profit attributable to each share.	$-1.87	$-2.20	$-2.62	$-1.80
Like basic EPS, but accounts for shares that could be created from stock options or convertible securities — a more conservative per-share profit figure.	$-1.87	$-2.20	$-2.62	$-1.80

Balance Sheet

	2025-12-31	2024-12-31	2022-12-31	2021-12-31
Cash and highly liquid short-term investments the company can access almost immediately.	$48.30M	$139.48M	$23.70M	$13.81M
Everything the company owns that has value — cash, property, inventory, investments, and more.	$533.43M	$450.98M	$215.65M	$295.94M
Everything the company owes — debt, unpaid bills, and other obligations.	$54.87M	$42.02M	$18.10M	$11.38M
What would be left for shareholders if the company sold all its assets and paid off all its debts — total assets minus total liabilities.	$478.56M	$408.96M	$197.55M	$284.57M

Cash Flow Statement

	2025-12-31	2024-12-31	2022-12-31	2021-12-31
Actual cash generated by the core business, as opposed to accounting profit, which can include non-cash items.	-$146.72M	-$104.35M	-$82.06M	-$50.69M
Cash spent on physical assets like property, equipment, and infrastructure to maintain or grow the business.	–	$159000	$363000	$1.57M
Cash left over after capital expenditures — money the company could use for dividends, buybacks, debt repayment, or reinvestment.	–	-$104.51M	-$82.43M	-$52.27M